Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib biomarker study in FLT3-ITD positive relapsed or refractory acute myeloid leukemia
jRCTs071200015Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Quizartinib resistance mechanism types and percentage of resistance mutations. Started Jul 2020; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs071200015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200015.